Core Viewpoint - A class action lawsuit has been filed against Paysafe Limited (NYSE: PSFE) for allegedly misleading investors about its business prospects during the period from March 4, 2025, to November 12, 2025 [1] Group 1: Allegations Against Paysafe Limited - The lawsuit claims that Paysafe failed to disclose significant exposure to a single high-risk client in its ecommerce business [1] - It is alleged that the company's credit loss reserves and/or write-offs were understated due to this exposure [1] - The complaint also states that Paysafe had undisclosed issues with higher risk Merchant Category Codes, complicating its client services [1] - These issues were likely to negatively impact the company's revenue growth and overall revenue mix [1] - As a result of these factors, Paysafe was unlikely to meet its previously issued financial guidance for fiscal year 2025 [1] Group 2: Impact on Stock Price - Following the revelation of these issues, Paysafe's stock price dropped by $2.80, or 27.6%, closing at $7.36 per share on November 13, 2025 [1] Group 3: Shareholder Actions - Shareholders may be eligible to participate in the class action and can submit their papers to the court by April 7, 2026, if they wish to serve as lead plaintiff [1] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [1] - All representation in the lawsuit is on a contingency fee basis, meaning shareholders pay no fees or expenses upfront [1]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who suffered significant losses in BlackRock TCP Capital Corp. (TCPC) due to alleged misleading statements regarding the company's business prospects and financial health [1]. Group 1: Allegations Against BlackRock TCP - The lawsuit claims that BlackRock TCP failed to disclose that its investments were not being valued appropriately, leading to understated unrealized losses and overstated net asset value (NAV) [1]. - It is alleged that the company's portfolio restructuring efforts were ineffective in resolving credit challenges or improving portfolio quality [1]. - The misleading statements made by the defendants regarding the company's operations and prospects lacked a reasonable basis, impacting investor decisions [1]. Group 2: Financial Disclosure and Market Reaction - On January 23, 2026, BlackRock TCP revealed that its NAV per share as of December 31, 2025, was between $7.05 and $7.09, which is 19% lower than the previous quarter and 23.4% lower than the previous year [1]. - Following this disclosure, BlackRock TCP's stock price dropped by $0.76, or 12.97%, closing at $5.10 per share on January 26, 2026 [1]. Group 3: Shareholder Actions - Shareholders interested in participating in the class action must file their papers with the court by April 6, 2026, to serve as lead plaintiff [1]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [1]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [1].

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding its Huntington's disease gene therapy drug, AMT-130, during the class period from September 24, 2025, to October 31, 2025 [1] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, with AMT-130 as its leading drug candidate aimed at slowing the progression of Huntington's disease [1] - The company faced significant scrutiny due to alleged material misstatements and omissions related to its clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [1] Legal Proceedings - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1] - Investors who purchased shares during the class period are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options, with a deadline to seek lead plaintiff status set for April 13, 2026 [1] Allegations - The complaint alleges that uniQure misrepresented the approval status of its Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA submission timeline [1] - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from its Phase I/II studies were adequate for BLA submission, leading to a significant drop in share price by over 49% [1]

Group 1 - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to Tri Pointe Homes, Inc.'s sale to Sumitomo Forestry Co., Ltd. for $47.00 per share [1] - The firm is also looking into VerifyMe, Inc.'s merger with Open World Ltd. [2] - The investigations may seek increased consideration, additional disclosures, and other relief for shareholders [2] Group 2 - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [3]

Core Viewpoint - The lawsuit against NuScale Power Corporation alleges securities fraud related to the company's partnership with ENTRA1 Energy LLC, claiming that the partnership posed undisclosed risks and led to significant financial losses for investors [4][5]. Summary by Sections Lawsuit Details - The lawsuit is filed on behalf of investors who purchased NuScale securities between May 13, 2025, and November 6, 2025, during which the company announced a partnership with ENTRA1 to commercialize its NuScale Power Modules technology [4]. - Allegations include that ENTRA1 had no significant experience in building or operating nuclear power projects, raising concerns about NuScale's commercialization strategy [5]. Financial Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses, which surged over 3,000% to $519 million from $17 million year-over-year, primarily due to a $495 million payment to ENTRA1 [6]. - This financial disclosure resulted in a net loss of $532 million for the quarter, compared to a $46 million loss in the previous year, causing the stock price to drop by approximately 14.4% in one day [6]. - Following this announcement, the stock price continued to decline, reaching a low of $17 per share by November 21, 2025, representing a drop of over 70% from its class period high of more than $57 per share [7].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Brown & Brown, Inc. and its officers or directors [1] Financial Performance - Brown & Brown reported a 2.8% decrease in organic revenue for Q4 2025, primarily due to a decline in flood claims processing revenue [3] - The company disclosed that 275 former employees joined a competitor, resulting in a loss of customers worth $23 million in annual revenue [3] Stock Market Reaction - Following the announcement of the financial results, Brown & Brown's stock price fell by $5.50 per share, or 6.91%, closing at $74.12 per share on January 27, 2026 [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Danone S.A. and its officers or directors [1] Group 1: Company Actions and Reactions - On January 21, 2026, Danone faced a contamination scare leading to a recall of infant milk formula after cereulide was detected in its Thai-origin Dumex Dulac 1, resulting in a 7.95% drop in its ADR price to $15.87 [3] - Following the initial recall news, Danone issued a press release on January 23, 2026, announcing a recall of select batches of its infant formula to comply with guidance, causing an additional 2.7% decline in its ADR price to $15.55 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Ardent Health, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on March 9, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ardent Health securities between July 18, 2024, and November 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the March 9, 2026 deadline [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable, claiming to employ an active monitoring process that was not actually utilized [4]. - It is claimed that Ardent Health did not maintain sufficient professional malpractice liability insurance, contrary to its public statements, leading to inflated accounts receivable reporting [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving ICON plc and its officers or directors, following a significant drop in the company's stock price after the announcement of an internal investigation into accounting practices [1][3]. Group 1: Company Announcement - On February 12, 2026, ICON announced it would release its fourth quarter and full year 2025 earnings results by April 30, 2026, and disclosed an ongoing internal investigation into its accounting practices initiated by the Audit Committee [3]. - The internal investigation was prompted by concerns reported to the Audit Committee through company management, indicating potential issues with the company's accounting controls [3]. Group 2: Stock Market Reaction - Following the announcement of the internal investigation, ICON's stock price experienced a significant decline, falling by $53.06 per share, or 39.85%, closing at $80.08 per share on February 12, 2026 [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of advocating for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Chagee Holdings Limited and its officers or directors [1]. Financial Performance - On August 29, 2025, Chagee reported its second-quarter 2025 financial results, highlighting increased competitive pressures and higher costs affecting near-term performance [3]. - Following the earnings call, Chagee's American Depositary Share (ADS) price dropped by $2.89, or 13.14%, closing at $19.11 per ADS on the same day [3].